Maxinovel Pty., Ltd.
11
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
Role: lead
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
Role: lead
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
Role: lead
MAX-10181 in Patients With Advanced Solid Tumor
Role: lead
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
Role: lead
A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects
Role: lead
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Role: lead
MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Role: lead
MAX-40279-01 in Patients With Advanced Solid Tumors
Role: lead
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
Role: lead
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Role: lead
All 11 trials loaded